A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478
Single-center, Double-blind, Randomized, Placebo-controlled, Three-part, First-in-human, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-541478 in Healthy Subjects
Sponsor: Idorsia Pharmaceuticals Ltd.
Terminated
Based on interim analysis, the Sponsor decided to terminate the study prematurely.
Other terminated trials from Idorsia Pharmaceuticals Ltd.
- Healthy Subjects · Phase PHASE1 · Dec 2017
- Pulmonary Arterial Hypertension · Phase PHASE2 · Sep 2011
- Pulmonary Arterial Hypertension · Phase PHASE2 · Sep 2011
- Aneurysmal Subarachnoid Hemorrhage · Phase PHASE3 · Jan 2011
- Heart Diseases · Phase PHASE3 · Mar 2008
More terminations from Idorsia Pharmaceuticals Ltd.
This PHASE1 trial investigates Healthy and is currently terminated or withdrawn. Idorsia Pharmaceuticals Ltd. leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Idorsia Pharmaceuticals Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .